drugset / Trial / NCT00790907

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

NCT00790907 ↗

Phase 4 Completed 3235 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated with fondaparinux.

Timeline

Start
2009-02
Primary completion
2010-05
Completion
2010-05

Outcome

Missed primary endpoint

registry p = 0.267; Odds Ratio (OR) 0.80 (95% CI 0.54 to 1.19); Regression, Logistic NCT00790907 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject fondaparinux background and standard dose UFH Unknown 50 iu/kg Intravenous
Subject fondaparinux background and standard dose UFH Unknown 60 iu/kg Intravenous
Subject fondaparinux background and standard dose UFH Unknown 85 iu/kg Intravenous
Background Fondaparinux Other / unclassified 2.5 mg Subcutaneous